BACKGROUND: In the United States, half of men with prostate cancer harbor the androgen-regulated gene fusion TMPRSS2:ERG. We hypothesized that men with TMPRSS2:ERG positive tumors are more responsive to androgen deprivation therapy (ADT). METHODS: We studied a cohort of 239 men with prostate cancer from the Physicians' Health Study and Health Professionals Follow-up Study who received ADT during their disease course. Fusion status was assessed on available tumor tissue by immunohistochemistry for ERG protein expression. We used Cox models to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for assessment of prostate cancer-specific mortality after ADT initiation. RESULTS: Roughly half of the men had stage T3 or higher tumors at diagnosis and 39% had Gleason 8-10 tumors. During an average follow up of 10.2 years, 42 men died from prostate cancer. There was a non-significant inverse association between positive fusion status and time to death from prostate cancer after ADT (multivariable HR: 0.76; 95% CI: 0.40-1.45). Harboring the TMPRSS2:ERG fusion was associated with a statistically significant lower risk of prostate cancer mortality among men who were treated with orchiectomy (multivariable HR: 0.13; 95% CI: 0.03-0.62), based on 15 events. CONCLUSIONS: Our results, combined with those from earlier studies, provide suggestive evidence that men with TMPRSS2:ERG positive tumors may have longer prostate cancer survival after ADT. Larger cohorts are needed for more robust results and to assess whether men with tumors harboring the fusion benefit from treatment with ADT in the (neo) adjuvant or metastatic setting specifically.
BACKGROUND: In the United States, half of men with prostate cancer harbor the androgen-regulated gene fusion TMPRSS2:ERG. We hypothesized that men with TMPRSS2:ERG positive tumors are more responsive to androgen deprivation therapy (ADT). METHODS: We studied a cohort of 239 men with prostate cancer from the Physicians' Health Study and Health Professionals Follow-up Study who received ADT during their disease course. Fusion status was assessed on available tumor tissue by immunohistochemistry for ERG protein expression. We used Cox models to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for assessment of prostate cancer-specific mortality after ADT initiation. RESULTS: Roughly half of the men had stage T3 or higher tumors at diagnosis and 39% had Gleason 8-10 tumors. During an average follow up of 10.2 years, 42 men died from prostate cancer. There was a non-significant inverse association between positive fusion status and time to death from prostate cancer after ADT (multivariable HR: 0.76; 95% CI: 0.40-1.45). Harboring the TMPRSS2:ERG fusion was associated with a statistically significant lower risk of prostate cancer mortality among men who were treated with orchiectomy (multivariable HR: 0.13; 95% CI: 0.03-0.62), based on 15 events. CONCLUSIONS: Our results, combined with those from earlier studies, provide suggestive evidence that men with TMPRSS2:ERG positive tumors may have longer prostate cancer survival after ADT. Larger cohorts are needed for more robust results and to assess whether men with tumors harboring the fusion benefit from treatment with ADT in the (neo) adjuvant or metastatic setting specifically.
Authors: Katri A Leinonen; Teemu T Tolonen; Hazel Bracken; Ulf-Håkan Stenman; Teuvo L J Tammela; Outi R Saramäki; Tapio Visakorpi Journal: Clin Cancer Res Date: 2010-05-04 Impact factor: 12.531
Authors: Kyung Park; Scott A Tomlins; Kumaran M Mudaliar; Ya-Lin Chiu; Raquel Esgueva; Rohit Mehra; Khalid Suleman; Sooryanarayana Varambally; John C Brenner; Theresa MacDonald; Abhishek Srivastava; Ashutosh K Tewari; Ubaradka Sathyanarayana; Dea Nagy; Gary Pestano; Lakshmi P Kunju; Francesca Demichelis; Arul M Chinnaiyan; Mark A Rubin Journal: Neoplasia Date: 2010-07 Impact factor: 5.715
Authors: Nuria Coll Bastus; Lara K Boyd; Xueying Mao; Elzbieta Stankiewicz; Sakunthala C Kudahetti; R Tim D Oliver; Daniel M Berney; Yong-Jie Lu Journal: Cancer Res Date: 2010-10-14 Impact factor: 12.701
Authors: R Jeffrey Karnes; John C Cheville; Cristiane M Ida; Thomas J Sebo; Asha A Nair; Hui Tang; Jan-Marie Munz; Farhad Kosari; George Vasmatzis Journal: Cancer Res Date: 2010-11-09 Impact factor: 12.701
Authors: Joost L Boormans; Karin G Hermans; Angelique C J Ziel-van der Made; Geert J H L van Leenders; Mark F Wildhagen; Laurence Collette; Fritz H Schröder; Jan Trapman; Paul C M S Verhagen Journal: Eur Urol Date: 2009-08-22 Impact factor: 20.096
Authors: Scott A Tomlins; Anders Bjartell; Arul M Chinnaiyan; Guido Jenster; Robert K Nam; Mark A Rubin; Jack A Schalken Journal: Eur Urol Date: 2009-04-24 Impact factor: 20.096
Authors: Jennifer R Stark; Sven Perner; Meir J Stampfer; Jennifer A Sinnott; Stephen Finn; Anna S Eisenstein; Jing Ma; Michelangelo Fiorentino; Tobias Kurth; Massimo Loda; Edward L Giovannucci; Mark A Rubin; Lorelei A Mucci Journal: J Clin Oncol Date: 2009-05-11 Impact factor: 44.544
Authors: J Michael Gaziano; Robert J Glynn; William G Christen; Tobias Kurth; Charlene Belanger; Jean MacFadyen; Vadim Bubes; JoAnn E Manson; Howard D Sesso; Julie E Buring Journal: JAMA Date: 2008-12-09 Impact factor: 56.272
Authors: G Attard; C Jameson; J Moreira; P Flohr; C Parker; D Dearnaley; C S Cooper; J S de Bono Journal: J Clin Pathol Date: 2008-12-09 Impact factor: 3.411
Authors: Chunru Lin; Liuqing Yang; Bogdan Tanasa; Kasey Hutt; Bong-gun Ju; Kenny Ohgi; Jie Zhang; David W Rose; Xiang-Dong Fu; Christopher K Glass; Michael G Rosenfeld Journal: Cell Date: 2009-12-11 Impact factor: 41.582
Authors: Primo N Lara; Andreas M Heilmann; Julia A Elvin; Mamta Parikh; Ralph de Vere White; Regina Gandour-Edwards; Christopher P Evans; Chong-Xian Pan; Alexa B Schrock; Rachel Erlich; Jeffrey S Ross; Philip J Stephens; John McPherson; Vincent A Miller; Siraj M Ali Journal: JCO Precis Oncol Date: 2017-11-02
Authors: Kanerva Lahdensuo; Andrew Erickson; Irena Saarinen; Heikki Seikkula; Johan Lundin; Mikael Lundin; Stig Nordling; Anna Bützow; Hanna Vasarainen; Peter J Boström; Pekka Taimen; Antti Rannikko; Tuomas Mirtti Journal: Mod Pathol Date: 2016-08-26 Impact factor: 7.842
Authors: Bhavna S Paratala; Sonia C Dolfi; Hossein Khiabanian; Lorna Rodriguez-Rodriguez; Shridar Ganesan; Kim M Hirshfield Journal: Biomark Cancer Date: 2016-02-11
Authors: Lauren K Jillson; Gabriel A Yette; Teemu D Laajala; Wayne D Tilley; James C Costello; Scott D Cramer Journal: Cancers (Basel) Date: 2021-06-30 Impact factor: 6.639